|
非洲多国参与的艾滋病预防药物试验失败
2009年12月15日 16:51:21 来源：新华网
新华网坎帕拉１２月１４日电（记者田野 陈静）乌干达卫生部部长马林加１４日宣布，一项由非洲多国参与、针对一种艾滋病防护制剂的大规模试验日前宣告失败。研究者表示，他们不会因此而终止同类药物的研究。
马林加是在此间举行的“第五届非洲艾滋病疫苗项目论坛”上宣布这一消息的。据他介绍，这项大规模药物试验始于２００５年９月，南非、赞比亚、坦桑尼亚和乌干达４国的６个研究中心参与，试验涉及９３８５名妇女。
这种名为ＰＲＯ２０００的凝胶状防护制剂由美国恩多制药公司生产，是一种女性外用药。试验结果显示，使用这种制剂的女性与使用安慰剂的对照组女性相比，其感染艾滋病病毒的风险并未有效降低。
乌干达研究人员指出，经过两年跟踪调查发现，乌干达参与试验的８４０名女性中，使用ＰＲＯ２０００的有１３０人感染艾滋病病毒，而使用安慰剂的对照组中有１２３人感染艾滋病病毒。
为期３天的“第五届非洲艾滋病疫苗项目论坛”１３日在坎帕拉开幕，来自全球２７个国家的２５０余名研究人员与会，他们共同讨论艾滋病防治领域所取得的进展。
Africa, involving many countries, HIV prevention fails drug test
December 15, 2009 16:51:21 Source: Xinhua
KAMPALA, December 14 (Xinhua Chen fields) Malinga 14, Uganda's Minister of Health announced a multi-country by the African participation in preparations for a large-scale trials of AIDS prevention has failed. The researchers said that they would not come to an end a similar drug research.
Malinga was held here, "the fifth African AIDS Vaccine Project Forum," announced the news. According to him, this large-scale drug testing began in September 2005, South Africa, Zambia, Tanzania and Uganda, four countries involved in six research centers, experiment involving 9385 women.
PRO2000, called the gelatinous protective agents from the United States Endor pharmaceutical company, is a female for external use. The results showed that women using this preparation and use of a placebo control group of women compared to the risk of HIV infection are not effectively reduced.
Uganda, the researchers pointed out that after two years of follow-up survey found that Uganda's involvement in trial 840 women, the use of PRO2000 There are 130 people infected with HIV, while the use of a placebo control group, there were 123 people infected with HIV.
3-day, "the fifth African AIDS Vaccine Project Forum" opened in Kampala on the 13th, from 27 countries worldwide and more than 250 researchers participating, they discuss AIDS prevention and the progress achieved in the field.
|
